Deucravacitinib is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Deucravacitinib is not recommended for use in combination with other potent immunosuppressants.
Topical Antifungal preparations
Deucravacitinib is a tyrosine kinase 2 (TYK2) inhibitor. TYK2 is a Janus kinase (JAK) family member. Deucravacitinib stabilizes an inhibitory interaction between the regulatory and catalytic domains of the enzyme by binding to the regulatory domain of TYK2. In cell-based assays, this results in allosteric inhibition of receptor-mediated activation of TYK2 and its subsequent activation of Signal Transducers and Activators of Transcription (STATs). In the JAK-STAT pathways, JAK kinases, including TYK2, function as homo- or heterodimers. In cell-based assays, TYK2 pairs with JAK1 to mediate multiple cytokine pathways and pairs with JAK2 to transmit signals. Currently, the precise mechanism linking TYK2 enzyme inhibition to therapeutic efficacy in the treatment of adults with moderate-to-severe plaque psoriasis is unknown.
Recommended Evaluations and Immunizations Prior to Treatment Initiation: Evaluate patients for active and latent tuberculosis (TB) infection prior to initiating treatment with Deucravacitinib. If positive, start treatment for TB prior to Deucravacitinib.
Recommended Dosage: The recommended dosage of Deucravacitinib is 6 mg taken orally once daily, with or without food. Do not crush, cut, or chew the tablets.
Pediatric Use: The safety and effectiveness in pediatric patients have not been established.
Geriatric Use: No overall differences in effectiveness have been observed between patients 65 years of age and older and younger adult patients.
Recommended Dosage in Patients with Hepatic Impairment: Deucravacitinib is not recommended in patients with severe hepatic impairment (Child-Pugh C). No dosage adjustment is needed for patients with mild to moderate hepatic impairment.
Renal Impairment: No dose adjustment is recommended in patients with mild, moderate, or severe renal impairment or in patients with end stage renal disease (ESRD) on dialysis.
Cyclosporine (dual Pgp/BCRP inhibitor), fluvoxamine (CYP1A2 inhibitor), ritonavir (CYP1A2 inducer), diflunisal (UGT 1A9 inhibitor), pyrimethamine (OCT1 inhibitor), famotidine (H2 receptor antagonist), or rabeprazole (proton pump inhibitor) did not significantly alter the pharmacokinetics of deucravacitinib. Rosuvastatin, methotrexate, mycophenolate mofetil (MMF), and oral contraceptives (norethindrone acetate and ethinyl estradiol) did not exhibit clinically significant differences in pharmacokinetics when co-administered with deucravacitinib.
Deucravacitinib is contraindicated in patients with a history of hypersensitivity reaction to Deucravacitinib or to any of the excipients of this preparation.
The most common side effect of Deucravacitinib include common cold, sore throat, and sinus infection (upper respiratory infections), cold sores (herpes simplex), sores on inner lips, gums, tongue, or roof of the mouth (canker sores), inflamed hair pores (folliculitis), acne. lt may cause serious allergic reactions including feeling faint or swelling in the face, eyelids, lips, mouth, tongue, or throat, trouble breathing or throat tightness or chest tightness or skin rash, hives etc.
Available data from case reports on Deucravacitinib use during pregnancy are insufficient to evaluate a drug-associated risk oi major birth defects, miscarriage. or adverse maternal or fetal outcomes. No effect on embryo-fetal development were seen in animal reproductive studies. There are no data on the presence of Deucravacitinib in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Deucravacitinib and any potential adverse effects on the breastfed infant from Deucravacitinib.
There is no experience regarding human overdosage.
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
.png&w=384&q=75)